Vir Biotechnology, Inc. (VIR) AI Stock Analysis

Vir Biotechnology, Inc. is a commercial-stage immunology company focused on developing and delivering therapies for the treatment and prevention of serious infectious diseases. Its pipeline includes Sotrovimab (VIR-7832), an antibody marketed under the Xevudy brand for treating and preventing COVID-19. The company is also advancing VIR-2218 and VIR-3434 to treat hepatitis B virus, VIR-2482 for influenza A virus prevention, and VIR-1111 for human immunodeficiency virus prevention. Founded in 2016 and headquartered in San Francisco, California, Vir collaborates with organizations including the Bill & Melinda Gates Foundation, the National Institutes of Health, and biopharmaceutical leaders.

Vir Biotechnology's annual revenue declined from $1.62B in FY2022 to $86.2M in FY2023, $74.2M in FY2024, and $68.6M in FY2025, yielding a 5-year revenue CAGR of -2.1%. Net income shifted from $515.8M in FY2022 to -$615.1M in FY2023, -$522.0M in FY2024, and -$438.0M in FY2025, while gross margin in FY2025 stood at 82.9% and operating margin was -682.7%. For the trailing twelve months ending June 30, 2026, revenue totaled $303.2M with an operating margin of 30.8% and EPS of -$1.76. In the latest quarter ending June 30, 2026, quarterly revenue growth was 19582.5% year-over-year, and quarterly earnings grew 58.5%.

As of June 30, 2026, Vir Biotechnology held $528.6M in cash and short-term investments against $93.3M in total debt, resulting in net cash of $435.3M. The company maintains solid liquidity with a current ratio of 6.04 and a debt-to-equity ratio of 0.09 across $982.5M in shareholders' equity. In FY2025, operating cash flow was -$391.8M and free cash flow was -$396.6M, alongside capital expenditures of $4.8M. Over the trailing five years, the company's share count increased 26.1%.

At a last close of $9.96 on October 16, 2026, Vir Biotechnology trades at a market cap of $1.69B and an enterprise value of $1.44B. The stock trades at a forward P/E of 4.3x, below the median of its US-listed Healthcare peers of 17.3x, and an EV-to-EBITDA multiple of 0.9x versus the peer median of 12.0x. Its price-to-sales multiple is 5.6x, compared to the peer median of 4.1x. Over the past year, Vir gained 71.7%, outperforming the S&P 500 ETF (SPY) return of 16.8%, though its 5-year return of -74.5% trails the SPY return of 83.0%.

Wall Street coverage consists of 6 Strong Buy and 3 Buy ratings, with no Hold, Sell, or Strong Sell ratings. The mean price target is $21.00, representing 110.8% upside compared to the last close of $9.96. For the fiscal year ending December 31, 2026, analysts estimate revenue of $245.2M and EPS of -$1.76. For the next fiscal year, 7 analysts project revenue to fall 69.0% to $76.1M, with EPS estimated at -$2.49. The company beat EPS estimates in 1 of the last 4 quarters and is scheduled to report earnings next on November 4, 2026.

This page is an AI-written research summary of Vir Biotechnology, Inc. (VIR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: VIR income statement, VIR balance sheet, VIR key metrics, VIR analyst forecast, VIR chart. See the VIR stock overview for the latest quote and news.